Results 161 to 170 of about 131,655 (304)

Early detection of type 2 diabetes mellitus‐associated cognitive dysfunction: The potential of amide proton transfer‐weighted imaging

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2859-2870, April 2026.
Abstract Aims Type 2 diabetes mellitus (T2DM) may lead to diabetes‐associated cognitive dysfunction (DACD). We aimed to develop an amide proton transfer‐weighted (APTw) magnetic resonance imaging (MRI) biomarker to assist early identification of T2DM with DACD. Materials and Methods The study included 27 T2DM patients, comprising 19 with mild cognitive
Ju‐wei Shao   +5 more
wiley   +1 more source

Duality for Evolutionary Equations With Applications to Null Controllability

open access: yesMathematical Methods in the Applied Sciences, Volume 49, Issue 5, Page 4144-4166, 30 March 2026.
ABSTRACT We study evolutionary equations in exponentially weighted L2$$ {\mathrm{L}}^2 $$‐spaces as introduced by Picard in 2009. First, for a given evolutionary equation, we explicitly describe the ν$$ \nu $$‐adjoint system, which turns out to describe a system backwards in time. We prove well‐posedness for the ν$$ \nu $$‐adjoint system. We then apply
Andreas Buchinger, Christian Seifert
wiley   +1 more source

Recent Insights Into Alzheimer's Disease: Advances in Pathophysiology and Therapeutic Strategies

open access: yesBrain Health, Volume 1, Issue 1, 26 March 2026.
ABSTRACT Alzheimer's disease (AD) is a complex neurodegenerative disorder driven by interplay among amyloid‐β (Aβ) plaques, tau neurofibrillary tangles, inflammation and comorbid pathologies. Recent advances in biomarkers and therapeutic approvals have reshaped our understanding of its pathophysiology and treatment landscape.
Jiong Shi   +3 more
wiley   +1 more source

Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ1R Agonists/HDAC Inhibitor Dual‐Acting Compounds

open access: yesChemMedChem, Volume 21, Issue 5, 13 March 2026.
This study explores the development of dual‐acting compounds combining σ1R agonists and histone deacetylase inhibitors (HDACi). Key findings include compound 2d and 3a's high affinity for σ1R and favorable pharmacokinetic profile and an in vivo determined σ1R agonist profile by reversing the effect of the σ1R antagonist BD‐1063.
Antonino N. Fallica   +16 more
wiley   +1 more source

A Comparison of the Effect of Remimazolam and Midazolam on Recovery and Preserved Memory Function for Patients with Dental Extraction Anxiety. [PDF]

open access: yesDrug Des Devel Ther
Jing Q   +14 more
europepmc   +1 more source

Pupil dilation as a marker of attention/effort in aging and mild cognitive impairment

open access: yesAlzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract INTRODUCTION Pupil dilation (PD) can be easily measured and reflects responses to subjectively salient or cognitively demanding events. It therefore holds promise as a cognitive marker, especially for individuals with mild cognitive impairment (MCI) or other neurodegenerative conditions with restricted abilities to respond in cognitive ...
Alina Zhunussova   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy